Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Queensland Health
Baxter
Chubb
Boehringer Ingelheim
McKinsey
Cerilliant
Deloitte
Fuji
Express Scripts

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,060,995

« Back to Dashboard

Which drugs does patent 9,060,995 protect, and when does it expire?

Patent 9,060,995 protects HETLIOZ and is included in one NDA.

This patent has fifty-six patent family members in sixteen countries.
Summary for Patent: 9,060,995
Title:Treatment of circadian rhythm disorders
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Inventor(s): Dressman; Marlene Michelle (Germantown, MD), Feeney; John Joseph (Olney, MD), Licamele; Louis William (Potomac, MD), Polymeropoulos; Mihael H. (Potomac, MD)
Assignee: Vanda Pharmaceuticals, Inc. (Washington, DC)
Application Number:14/301,799
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,060,995

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,060,995

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,730,910 Treatment of circadian rhythm disorders ➤ Subscribe
2,017,087,122 ➤ Subscribe
8,785,492 Treatment of circadian rhythm disorders ➤ Subscribe
RE46604 Treatment of circadian rhythm disorders ➤ Subscribe
9,549,913 Treatment of circadian rhythm disorders ➤ Subscribe
9,539,234 Treatment of circadian rhythm disorders ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,060,995

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013211878 ➤ Subscribe
Australia 2013211880 ➤ Subscribe
Australia 2013361459 ➤ Subscribe
Australia 2015206797 ➤ Subscribe
Australia 2016204178 ➤ Subscribe
Australia 2016204217 ➤ Subscribe
Canada 2861108 ➤ Subscribe
Canada 2861111 ➤ Subscribe
Canada 2893542 ➤ Subscribe
Canada 2936504 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Merck
Citi
UBS
Daiichi Sankyo
Teva
Fish and Richardson
QuintilesIMS
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot